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CHAPTER I 
LITERATURE REVIEW 
A. Introduction 
 
The rising prevalence of obesity in the past 20 years underscores the need to 
understand the biology and key regulatory processes involved in the 
development of obesity.  Adipogenesis, or the formation of new adipocytes from 
precursor cells, is one such regulatory process. Fully mature, differentiated 
adipocytes accumulate lipid and contribute to fat cell mass (18). Although vitamin 
D generally promotes cell differentiation, its role in adipocyte differentiation and 
proliferation is less clear. Vitamin D circulates as 25-hydroxyvitamin D (25-D), 
which is converted to the vitamin’s active form, 1,25-dihydroxyvitamin D (1,25-D) 
by the renal 1α-hydroxylase (17, 31).  Recent studies indicate that this activating 
enzyme 1α-hydroxylase is also expressed in non-renal tissues such as placenta, 
prostate, colon, breast (16) but expression of the 1-α hydroxylase has not been 
described in adipocytes. Epidemiologic studies show a negative correlation 
between serum levels of 25-D and adiposity, and cell culture studies suggest that 
1,25-D may influence adipogenesis (20, 32). The murine 3T3-L1 preadipocyte 
cell line has been widely used to study the adipogenic process (23,19).  Recent 
findings in this cell line indicate that 1,25-D inhibits differentiation of 
preadipocytes to mature adipocytes (13,3,7,24). Furthermore, 1,25-D exerts its 
effect through binding with the nuclear receptor VDR (13,3).  However, no 
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studies have investigated the role of 25-D in these cells. This research is 
designed to investigate the roles of both 25-D and 1,25-D  in adipocyte 
differentiation in murine 3T3-L1 cells and to determine whether these cells 
express the 1α-hydroxylase. 
B. Overview of Obesity  
 
The growing prevalence of obesity is one of the biggest public health 
concerns in the US and around the world. There has been a sharp rise in obesity 
over the past 20 years (40, 41, 42). Figure 1, shows the growing trends in obesity 
in the US population. In the 1990s the Behavioral Risk Factor Surveillance 
System (BRFSS) data shows 10 states with <10% obesity and no state having 
>15% prevalence in obesity. In comparison there has been dramatic rise in 
obesity prevalence 2006 to only 4 states with <20% obesity and 22 states with a 
prevalence of >25% obesity of which 2 states had >30% prevalence of obesity 
(39).  
 Obesity is defined as body mass index (BMI) > 30. The number of people 
in the obese and morbidly obese (BMI>40) category has seen a dramatic 
increase since 1990 (41,42, 40). Obesity increases an individual’s risk to 
comorbidities like type 2 diabetes, cardiovascular diseases and certain cancers 
(41,51).  Obesity also increases an individual’s rate of mortality from acute or 
chronic disease. Obesity is a result of a constant increase in energy intake and 
lower output. There are many factors contributing to obesity including high 
energy intake, decreased physical activity, sedentary lifestyle, increase in fast 
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food etc (42). However, understanding the science behind obesity is an important 
aspect in the prevention of this disorder. Over the past decade there have been a 
number of studies focusing on the science of obesity and the key regulatory 
processes involved in the development of obesity.  
 
Figure: 1. Obesity trends in the US. This figure shows the growing trends in 
obesity in the US population. In the 1990s the BRFSS data show 10 states with 
<10% obesity and no state having >15% prevalence in obesity. In comparison 
there has been dramatic rise in obesity prevalence 2006 to only 4 states with 
<20%obesity and 22 states with a prevalence of >25% obesity of which 2 states 
had >30% prevalence of obesity.  
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C. Adipose Tissue 
 
Obesity very simply can be defined as an unhealthy increase in the adipose 
tissue mass. In humans, adipose tissue is of two types brown and white.  The 
role of both are opposite of each other.   
Brown adipose tissue (BAT): It is present in significant amounts in infants and 
is negligible in adults. It gets its color due to the high number of mitichondria and 
the rich blood flow through it. It contributes to thermogenesis which is the 
involuntary heat production or release of energy through physical activities like 
shivering etc in response to cold (45).  BAT consists of a protein in its inner 
mitochondrial membrane called thermogenin also called uncoupling protein-1 
(UCP-1) which dissipates energy through the uncoupling of energy yielding 
nutrients and ATP production (45). UCP-2 and UCP-3 are the other uncoupling 
proteins identified so far in other tissues of the body as well (47). 
White adipose tissue (WAT):  White adipose tissue primarily stores energy as 
triacylglycerols. Majority of adipose tissue in our body is white adipose. They are 
present as subcutaneous fat and visceral fat. The body can store limitless 
amount of fat.  Adipose tissue is made up primarily of adipocytes. Adipocytes are 
rich sources of energy made up of 80% lipid and 20% of water and protein (50).  
They are capable of growing 50 times in weight (50). In addition to adipocytes the 
adipose tissue also consists of macrophages, preadipocytes, fibroblasts, loose 
connective tissue and various cell types (43).  
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1. Functions of Adipose Tissue 
 
Energy Storage: One of the main functions of the adipose tissue is in energy 
storage. Excessive energy is stored as triacylglycerols in the adipose tissue. 
During starvation, this can be mobilized for energy.  
Insulation: Fat layer beneath our skin serves as an insulating layer.  
Protection: Many important organs are surrounded with a layer of fat which 
protects it from injury. 
 Adipose tissue produces and regulates certain cytokines which are proteins 
called adipokines. These proteins are mediators, which act as hormones and 
they are called adipocytokines / adipokines.  These adipokines have been 
implicated for their role in different mechanisms like regulation of energy balance, 
insulin action, glucose metabolism, inflammation and immunity (43). Some of the 
adipokines being studied are leptin, adiponectin, resistin, visfatin, TNF-α etc. 
Leptin is known to regulate appetite, food intake and energy expenditure. 
Adiponectin plays a beneficial role in insulin resistance, atherosclerosis, 
inflammation and dyslipidemia (52). Similar to adiponectin, visfatin also plays a 
beneficiary role in glucose metabolism by affecting the insulin signaling pathways 
(53). TNF-α is known for its pro inflammatory role.  In general adipokines play a 
dual role of friend and foe in obesity and development of obesity related 
comorbidities (51). 
 
5 
  
 
2. Development of Obesity and Adipogenesis 
 
Obesity is a state of positive energy balance leading to increase in 
adipose tissue mass. Adipose tissue mass increase relates to the changes in the 
size or number of adipocytes.  
Adipose tissue mass can increase in two ways: hyperplasia, which is 
characterized by an increase in the cell number or hypertrophy, which is 
characterized by an increase in the size of the cell (19). 
Adipocytes develop from precursor cells, called preadipocytes, which are 
fibroblast-like cells. Adipogenesis is defined as the formation of round lipid-filled 
adipocytes from preadipocytes and is one of the key regulatory processes 
involved in the development of obesity (3). These newly formed cells can further 
increase in size by accumulating more lipid droplets. When these adipocytes 
exhaust their storage capacity, there is a consequent increase in cell number 
(19).  
Thus, both increase in cell number and cell size contribute to adipose mass.  
Adipogenesis occurs throughout the lifetime  in response to normal cell turnover 
and to excess energy to be stored as fat mass (48).  
 
3. Adipocyte Development 
 
The adipose lineage originates from multipotent mesodermal stem cells 
(19). The precursor cells are present in the stroma of the adipose tissue which 
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can undergo commitment to the adipocyte lineage through a multi-step process 
to form preadipocytes (19). These preadipocytes can undergo terminal 
differentiation under an adipogenic hormonal milieu to form mature fat-filled 
adipocytes. These mature adipocytes can express adipogenic markers such as 
fatty acid synthase (FAS), lipoprotein lipase (LPL), acetyl-CoA carboxylase, 
glucose transporter 4 (GLUT4), fatty acid binding protein (aP2) and have the 
capacity to accumulate large quantities of triacylglycerol (13). 
The adipocyte differentiation occurs in a series of well defined steps. 
Commitment: In this phase, pluripotent mesenchymal stem cells undergo 
determination to the adipose lineage in response to certain signaling events (19), 
although It is unclear what actually are these signaling factors. It is speculated 
that it may be a gene or the mature adipocyte which secretes some signaling 
molecule (19,23).  The preadipocytes are formed in this phase. It is suggested 
that BMP4 could possibly be the signal for this determination (23). 
Recruitment and Proliferation of adipocytes: In this phase, the preadipocytes 
proliferate and increase in numbers. The preadipocytes undergo a growth arrest 
phase after which they undergo 2 more rounds of proliferation before the next 
phase (19). This is called mitotic clonal expansion. It is controversial if mitotic 
clonal expansion is absolutely necessary for terminal differentiation. However, 
certain important transcriptional factors are generated during this phase which 
regulate the terminal differentiation to mature adipocytes (19,23). 
Terminal Differentiation: This is the final phase where the preadipocytes 
undergo the final step to form the mature lipid filled adipocyte. These adipocytes 
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produce proteins required for lipid transport and synthesis, insulin sensitivity and 
other adipocyte specific proteins (23). On introduction of hormonal inducers of 
differentiation such as insulin, dexamethasone and 3-isobutyl-1-methylxanthine, 
the preadipocytes express a cascade of transcriptional factors, coactivators and 
cell-cycle proteins which trigger the necessary steps to induce terminal 
differentiation (19). The differentiation process is complex and under the 
regulation of multiple inhibitory and stimulatory signals. Figure 2 shows the steps 
involved in adipocyte differentiation. After determination to the adipocyte lineage, 
the preadipocytes increase in number and undergo differentiation to mature 
adipocytes, which then can accumulate triacylglycerol and increase in size. 
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Figure: 2. Adipocyte Development. This figure shows the steps involved in 
adipocyte differentiation. After determination to the adipocyte lineage the 
preadipocytes increase in number and undergo differentiation to mature 
adipocyte, which can accumulate triacylglycerol and increase in size. 
 
 
 
 
 
 
9 
  
4. Adipogenic Transcription Factors 
 
The most important transcriptional factors involved in the regulation of 
differentiation are the PPAR family and the CCAAT/enhancer-binding proteins. 
Peroxisome proliferators-activated receptors (PPARs) family:  
They belong to the nuclear receptor family like retinoic acid receptors and 
vitamin D3 receptors. There are 3 members of the PPAR family α, β and γ (19). 
The PPARs have a ligand independent transactivation domain, DNA binding 
domain and a ligand binding, a dimerization domain with a ligand-dependent 
transactivation domain (19). PPAR forms a heterodimer with RXR prior to binding 
of DNA to the peroxisome proliferators-activated receptor element in the 
promoter region of the target genes. Of the different members of PPAR family the 
chief regulator of adipogenesis is PPARγ (19). 
PPARγ : It is the key regulator of adipogenesis. It is important for promotion of 
differentiation to the mature adipocyte and for maintenance of the differentiated 
state (19, 23).  It is expressed during differentiation and is responsible for 
activation of adipogenic genes. Some of the genes activated are aP2, lipoprotein 
lipase, acyl CoA synthase and phosphoenolcarboxykinase. These genes are 
involved in fatty acid transport, uptake and storage. Studies have demonstrated 
the importance of PPARγ in the adipogenic process. Overexpression of PPARγ in 
vitro induces adipocyte differentiation in fibroblasts (19, 23).  PPARγ is required 
for adipogenesis and no factor has been identified which promotes adipogenesis 
in the absence of PPARγ (23). Thiazolidinedione (TZD), an anti-diabetic drug is a 
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ligand for PPARγ (23). Studies conducted so far have not identified an 
endogenous ligand for PPARγ (23). PPARγ has 3 isoforms PPARγ1, γ2 and γ3. 
PPARγ1 and γ2 are expressed in adipocytes are important regulators of 
adipogenesis (19). Few studies have identified PPARγ2 as the main isoform 
required for adipogenesis, while others have suggested both are required for 
adipogenesis (19). The CCAAT/enhancer-binding protein C/EBPβ  and C/EBPδ 
are required for the activation of PPARγ expression (23,19). However their role is 
unclear. Sterol response element-binding protein-1c (SREBP1c) can also 
influence the activation of PPARγ (10). It is understood that PPARγ along with 
C/EBPα are responsible for activation of many adipogenic genes involved in 
adipogenesis (19).  
CCAAT/enhancer-binding Proteins (C/EBPs):  
They are involved in promotion of adipogenesis. They consist of 6 isoforms α, 
β, γ, δ, ζ(CHOP-10), and ε. All except the ε form is involved in adipogenesis (19). 
C/EBPβ and δ are involved in the early regulation of the adipogenesis. cAMP 
response element binding protein (CREB) is responsible for the transcriptional 
activation of C/EBPβ (19). Addition of differentiation inducers like insulin and 
cAMP leads to the phosphorylation of CREB and its effects early in the 
differentiation process. C/EBPβ is required for the mitotic clonal expansion to 
occur (19). The C/EBPβ and δ is responsible for activation of C/EBPα (19). Once 
expressed, C/EBPα continues to be active by an autoactive mechanism (19).  
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C/EBPα is essential for differentiation and it activates several adipogenic genes 
(19). Cell culture study has shown that blocking of C/EBPα inhibit adipocyte 
differentiation (19).  Studies conducted on C/EBPα (-/-) mice shows defects in 
accumulation of lipid (19).  It is expressed after the clonal expansion phase in 
differentiation as it has anti-mitotic activity (19). Other C/EBP isoforms CHOP 
and C/EBPγ are anti-adipogenic (23). 
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Figure 3: Transcription factors and adipogenic genes during Differentiation. This 
shows the expression of the various transcription factors after induction of 
differentiation leading to expression of the adipogenic genes. The dotted lines 
signify a potential activation of the particular factor.  CREB – cAMP response 
element binding protein, SREBP-1c – sterol regulatory element binding protein 1c, 
SCD1 – stearoyl- CoA desaturase 1, aP2- adipocyte protein 2 a fatty acid binding 
protein, GLUT4 – glucose transporter and OB gene – the obese gene.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Modified from: Otto TC, Lane MD. Adipose development: from stem cell to adipocyte. Crit Rev 
Biochem Mol Biol 2005;40:229-42.) 
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5. Cell Culture Models 
 
Much of our knowledge about adipogenesis or fat cell biology has been 
through in-vitro experimental cell culture model systems. There are 2 types of cell 
culture models: 
Primary Culture: They are isolated directly from vascular stroma of 
adipose tissues from humans or animals e.g. human preadipocytes (phPA), pigs 
and rodents (19,18). These cells are difficult to isolate and have a limited life-
span. They are also expensive. Furthermore, these cells are heterogenous which 
means they do not exhibit similar characteristics after each passage (9). This cell 
model can be used to confirm the results seen in cell line models. 
Cell Lines: They are of two types: multipotent fibroblastic cell lines which 
are not committed and have adipogenic potential, e.g. NIH-3T3, Balb/c3T3, C3H 
10T1/2 etc (9) and established preadipocyte cell lines which have undergone 
commitment to the adipose lineage (9). Examples of these cell lines are 3T3-L1, 
Ob1771, 3T3F442A, TA1, Ob17 etc.  They exhibit morphology and biochemical 
properties similar to in vivo adipocytes. They are homogenous and have a long 
life span in culture (9).  
3T3-L1 preadipocytes: The murine 3T3-L1 preadipocyte cell line is a 
widely used model to investigate the adipocyte differentiation process. They are 
derived from cloned subline of Swiss 3T3 mouse embryo fibroblasts (40). This 
model was developed by Howard Green and colleagues (40). They can undergo 
differentiation in culture and exhibit morphology and biochemical properties 
similar to adipocytes. Furthermore, when transplanted subcutaneously into BALB 
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C (athymic) nude mice these preadipocytes differentiate and develop into tissue 
similar to adipose tissue (25). The 3T3-L1 preadipocytes can grow exponentially 
in culture and when fully confluent reach a growth arrest and enter a stable 
resting state (40). The post confluent 3T3-L1 preadipocytes when treated to a 
hormonal cocktail of differentiation inducers consisting of dexamethasone, insulin 
and 3-isobutyl-1-methylxanthine (MIX) which increases cAMP can differentiate to 
form mature lipid-filled adipocytes (28). This hormonal cocktail is abbreviated as 
MDI (25). The preadipocytes differentiate to mature adipocytes between 4 to 8 
days.  
 
6. Hormonal Inducers of Adipogenesis 
 
Adipocyte differentiation is influenced by endocrine signals (9). The hormonal 
inducers of differentiation in most cell systems are insulin, IGF-1, growth 
hormone, glucocorticoid and cAMP. In 3T3-L1 cells a mixture of insulin, 
dexamethasone (which works as a glucocorticoid), fetal bovine serum (which 
supplies the growth hormone) and 3-isobutyl-1-methylxanthine called MIX 
(increases intracellular cAMP) induce differentiation in postconfluent 
preadipocytes. 
Insulin/IGF-1: Insulin promotes adipocyte differentiation. Preadipocytes hardly 
express insulin receptors but have IGF-1 receptors. Insulin mediates its 
adipogenic actions in preadipocytes through the IGF-1 receptor signaling. 
However, as the differentiation progresses and mature adipocyte is formed they 
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express more insulin receptors than IGF-1 receptors (48, 9, 23). Insulin and IGF-
1 activate several signal transduction pathways which leads to the adipogenic 
effects exerted by them (48,23). 
Glucocorticoids: Glucocorticoids are stimulators of differentiation especially in 
3T3-L1 cells. Dexamethasone (Dex) functions as the glucocorticoid and exerts its 
adipogenic effects through the glucocorticoid receptor (GR).  Dex appears to 
induce the expression of C/EBPδ which causes its adipogenic activity (48). 
However, this effect is unclear as studies have demonstrated that overexpression 
of C/EBPδ in cells still require Dex for adipogenesis signifying another 
mechanism through which Dex operates (48). Another potential role of 
glucocorticoids is inhibition of phospholipase A2. This inhibition leads to 
decreased prostaglandin induced inhibition of differentiation (9). 
Growth Hormone: Growth hormone has been shown to promote adipogenesis 
in preadipocyte cell lines, but appears to not have the same effect in primary cell 
lines (9). In 3T3-L1 cells fetal bovine serum provides the growth hormone 
required for differentiation.  
cAMP: The phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine acts as 
the agent that increases intracellular cAMP levels (48, 9). 
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D. Vitamin D 
 
Vitamin D is a seco-steroid hormone and is well-known for its classic role 
in calcium and phosphorus homeostasis. It is a fat soluble vitamin and deficiency 
of which causes bone deformities in children called rickets and in adults causes 
osteomalacia. Unlike typical vitamins which need to given in small amounts 
through the diet or supplements, vitamin D can be synthesized endogenously 
through photolysis of 7-dehydrocholesterol in the skin.  
 
1. Cutaneous Synthesis of Vitamin D 
 
Vitamin D is synthesized in the body either from sunlight or from dietary 
sources. The UVB rays with wavelengths 290 and 315nm from the sunlight acts 
on 7-dehydrocholesterol present on the skin to make previtamin D3. Previtamin 
D gets converted to Vitamin D by thermal transformation. Prolonged exposure to 
sunlight can lead to conversion of previtamin D to inactive catabolic compounds 
called lumisterol and tachysterol (2).  Prolonged sun exposure can also cause 
vitamin D to degrade to suprasterol I, suprasterol II and 5,6-trans-vitamin D (2). 
The newly formed Vitamin D enters the circulation and binds to a specific vitamin 
D binding protein called α1-globulin. 
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2. Activation of Vitamin D 
 
Vitamin D bound to α1-globulin travels to the liver where it gets 
hydroxylated at carbon 25 by 25-hydroxylase (CYP27A) to form 25-
hydroxyvitamin D (25-D). This form is the main circulating form of the vitamin. 
The normal range for 25-D in the blood is between 20-87 nmol/L and it has a half 
life of 3 weeks (2).  The 25-hydroxyvitamin D further undergoes hydroxylation 
either at the 1 position by renal enzyme 1α-hydroxylase (CYP27B1). Renal 1α-
hydroxylase causes hydroxylation to 1,25-dihydroxyvitamin D. This is the active 
form of vitamin D and is capable of producing the functional effects of vitamin D.  
The ubiquitous enzyme 24-hydroxylase (CYP24) can inactive both vitamin D 
metabolites, it converts 25-D to 24,25-dihydroxyvitamin D and 1,25-D to 1,24,25 
(OH)3 (calcitetrol). These metabolites are further degraded and excreted out as 
calcitroic acid. CYP24 expression is regulated by 1,25-D levels (27).  Vitamin D 
from the diet enters the circulation directly and can undergo similar 
hydroxylations in the liver and kidneys. Vitamin D from dietary sources are taken 
up by enterocytes and incorporated into chylomicrons. These chylomicrons enter 
the venous blood stream after being released by the enterocytes into the 
lymphatic system and then drained into the blood stream (2). The chylomicron 
remnants reaches the liver where the vitamin D is hydroxylated to 25-D by 25-
hydroxylase and enters the circulation bound to vitamin D binding protein (17). It 
can undergo further hydroxylation in the kidney. Figure 4, shows the various 
vitamin D metabolites derived through cutaneous synthesis and diet to the 
formation of the 25-hydroxyvitamin D3 (circulating form) and its conversion to 
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1,25-dihydroxyvitamin D3 (active form) and their respective inactivation to 
calcitroic acid. Also shown are the major enzymes involved in the activation and 
inactivation of these metabolites. 
 
3. Dietary sources of vitamin D 
 
Fortified milk, eggs from hens fed vitamin D-fortified feed, fatty fish, fish 
oils, and animal liver (2). 
RDA/AI: Vitamin D does not have a set RDA because an estimated 
average requirement (EAR) could not be set due to results being confounded by 
sun exposure. An adequate intake (AI) is set for vitamin D. The AIs are as 
follows:  
Infants to 50 years old   200IU/day (5µg) 
51 to 70 years old  400 IU/day (10µg) 
Over 70 years  600 IU/day (15µg) 
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Figure: 4. Vitamin D Metabolites. This shows the various vitamin D metabolites 
derived through cutaneous synthesis and diet to the formation of the 25-
hydroxyvitamin D3 (circulating form) and its conversion to 1,25-dihydroxyvitamin 
D3 (active form) and their respective inactivation to calcitroic acid. The major 
enzymes involved in the activation and inactivation of these metabolites. 
CYP27A – 25-hydroxylase, CYP27B1 - 1α-hydroxylase and CYP24 – 24-
hydroxylase.  
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4. Factors Affecting Vitamin D Synthesis 
 
Vitamin D synthesis from sunlight is affected by various factors. The 
following are some of the factors affecting its synthesis from sunlight: 
(i) Clothing: It blocks cutaneous vitamin D synthesis. 
(ii) Latitude: During the months from November through February people in 
northern latitudes do not make vitamin D from sun exposure. This is because the 
angle of the sun rays blocks the wavelengths required for conversion of 7-
dehydrocholesterol to previtamin D. Hence no cutaneous synthesis of vitamin D 
occurs (46). 
(iii) Skin tone: Melanin the skin pigment acts as a natural sunscreen, hence 
people with darker skin require much more sun exposure than light skinned 
people for cutaneous vitamin D synthesis. 
(iv) Sunscreen: Sunscreens contain SPF-8 which blocks UV B rays required for 
its synthesis by the skin. 
(v) Age: Aging causes a decrease in vitamin D synthesis, absorption and 
metabolism. Aging can cause a decrease in synthesis of vitamin D by skin due to 
decreased 7-dehydrocholesterol levels. Hence there is a decrease in serum 
levels of 25-D. Aging can also lower levels of intestinal vitamin D receptors (46). 
(vi) Temperature: Prolonged sun exposure and increased skin temperature leads 
to formation of vitamin D degradation products. 
(vii) Heredity: Vitamin D polymorphisms also decrease vitamin D formation.  
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5. Vitamin D Metabolism 
 
The main function of vitamin D is maintaining the calcium and phosphorus 
levels in the blood. Vitamin D level is regulated by PTH, 1,25-D (calcitriol) and 
serum calcium and phosphorus levels.   
Parathyroid Hormone - PTH is secreted by the parathyroid glands located 
in the hypothalamus. The parathyroid glands have cell surface calcium sensors 
which can detect low levels of calcium in the blood. PTH is released in response 
to hypocalcemia. Increase in PTH levels is sensed by PTH sensors in the kidney 
(2). Once PTH is released it acts on the kidneys by increasing the activity of 1α-
hydroxylase which causes increased production of 1,25-D (calcitriol) from 25-D. 
1,25-D brings about the effects of increasing serum calcium levels through the 
intestine and bones. 
Calcitriol (1,25-D) – It is the active metabolite of vitamin D and it’s main functions 
is to regulate serum calcium levels by affecting the intestine and bone.   
Intestine - Calcitriol directly increases intestinal absorption of calcium by 
increasing the activity of proteins like calbindin. Calbindin is responsible for the 
transport of calcium across the intestinal mucosa. It also increases activity of 
other proteins like alkaline phosphatase, calmodulin, low-affinity calcium-
dependent ATPases, brush border actin (17). 
  Bone- Calcitriol can indirectly affect osteoclastic activity and increase 
serum calcium levels through bone resorption. Calcitriol responsive vitamin D 
receptors are present on osteoblasts. 1,25-D mobilizes bone to release calcium 
through its action on osteoblasts. Calcitriol enhances the production of osteoclast 
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sensitive cytokines like IL-6 and IL-12 which can regulate osteoclastic activity 
and bring about bone resorption (17). In turn, calcitriol levels can negatively 
regulate PTH. Low levels of calcitriol increase PTH secretion whereas high levels 
inhibit PTH secretion (2). Further, high 1,25-D levels downregulates the activity of 
renal 1α-hydroxylase and upregulates 24-hydroxylase activity (27). This brings 
about the catabolic breakdown of 1,25-D  to 1,24,25-D (calcitetrol) can occur. 
1α-hydroxylase – It is the renal enzyme involved in the activation of 25-D 
to 1,25D.  1,25-D negatively regulates the renal 1 α-hydroxylase activity. 
Disruption of the 1 α-hydroxylase gene in null mutant mice results in 
hypocalcemia, hyperparathyroidism, growth retardation, osteomalacia and 
reproductive dysfunction (27). Recent studies have demonstrated the presence 
of 1α-hydroxylase in extra-renal tissues like immune cells, breast, pancreas and 
the prostate (16).  In the extra renal tissues this enzyme is influenced by 
cytokines (37,15). 1,25-D regulates cell differentiation function in certain tissues 
and the presence of 1α-hydroxylase in these tissues could play an important role 
in the paracrine regulation of 1,25-D (15). 
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6. Mechanism of Action of Vitamin D 
 
Vitamin D exerts its metabolic responses either by rapid response or non-
genomic responses of 1,25-D or through genomic response. 
Genomic Responses: It is also called less rapid or genome-initiated 
responses. These responses can take minutes to hours or days. The genomic 
responses of 1,25-D is mediated through the nuclear vitamin D receptor (VDR) 
(8).  1,25-D binds to VDR on the nucleus of the cell and binding to the ligand 
brings about a conformational change and facilitates the formation of a 
heterodimer with retinoid X receptor (RXR) (8). This further causes 
phosphorylation to activate binding to the VDRE (vitamin D receptor element) in 
the promoter region of target genes and causes the upregulation of vitamin D 
responsive genes thereby causing the tissue specific responses (8). Some of the 
genes upregulated by 1,25-D are calbindin D, osteocalcin, osteopontin, plasma 
membrane calcium pump, interleukin-1, interleukin-6 (2, 8). 
VDR: It is a 50 kDa nuclear receptor which has a high affinity to 1,25-D. It 
is a member of the nuclear receptor family of ligand activated transcription 
factors (27).  It was first found in the intestinal mucosa, but now is found in other 
tissues like the kidneys, bone, parathyroid glands, β-cells of the pancreas, 
placenta, pituitary, uterus, mammary glands, skin, thymus, monocytes, 
macrophages and T lymphocytes (2). The primary amino acid sequence of VDR 
has 5 functional domains which include regions for nuclear localization, DNA 
binding, heterodimerization, ligand binding and transcriptional activation (17). 
Regulation of gene transcription is dependent on the ligand binding to the 
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receptor (17).  An unoccupied VDR does not bring about the gene transcription 
as that of a VDR bound to its ligand 1,25-D. Shape of the ligand is also an 
important aspect for the up or downregulation of the genomic responses. VDR 
bound to the hat icon shape of 1,25-D leads to the appropriate gene responses 
(17).  
Non-Genomic or Rapid responses: It is also called rapid responses as it 
takes a few seconds or minutes for the tissue specific responses. These 
responses are mediated by a cell membrane receptor for vitamin D called 
MARRS (membrane activated rapid response steroid binding protein) (44). The 
binding of the 1,25-D to the cell membrane receptor causes a number of signal 
transduction pathways which leads to the corresponding physiological response 
(8). In enterocytes, ligand binding to the receptor causes G-protein activation 
leading to phospholipase C linked hydrolysis of phosphatidylinositol 
bisphosphate (PIP2). This causes release of diacylglycerol and inositol 
triphosphate (IP3). IP3 leads to the opening of calcium transport channels in the 
ER leading to the release of Ca+ ions which activates calcium dependent 
proteins like calmodulin.  This brings about the appropriate physiological 
responses. Diacylglycerol leads to activation of protein kinase C and mitogen 
activated (MAP) kinases which in turn also causes the physiological responses.  
These physiological responses include transcaltachia, activation of voltage-gated 
calcium channels, increase in intracellular calcium, induction of phospholipids 
and sphingolipid turnover (2). 
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7. Non-Classical Functions of Vitamin D 
 
Cell differentiation and antiproliferation: 1,25-D promotes terminal 
differentiation of keratinocytes and inhibits proliferation and this has been used in 
the treatment of psoriasis (2).  In vitro studies, vitamin D has been shown to 
suppress cancer through cell cycle arrest and growth inhibition of the proliferating 
cancer cells (4). 1,25-D downregulates inflammatory markers such as IL-2 and 
IL-12 and exerts its antiproliferative effect (15).  Cancer research has shown the 
presence of VDR, 1 α-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24) in 
colon, prostate and breast cancer cells. It has been suggested that the local 
production of 1,25-D in these cells are responsible for the antiproliferative effects 
(34). Furthermore, in MCF-7 human breast cancer line the malignant cells 
regulate 24-hydroxylase expression and through this mechanism protect itself 
from the anti-cancer effects of 1,25-D (34).  
Endocrine glands: Vitamin D has been implicated in the pathogenesis of 
type 1 diabetes (35). Vitamin D may play a protective role in type 1 diabetes 
possibly due to its role in β-cell function and normal insulin secretion (35,15). It is 
required for normal insulin secretion. 1,25-D can alter T-cell differentiation and 
induce cytokine secretion. Studies in NOD mice, an animal model for type 1 
diabetes shows that vitamin D deficiency early in life causes type 1 diabetes (35).   
Immune system: 1,25-D has potent immunomodulatory effects and may 
have a preventive effect in autoimmune deficiency (15).  A recent study has a 
demonstrated a strong inverse correlation between vitamin D levels and multiple 
sclerosis (MS), a autoimmune characterized by demyelination of central nervous 
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system (36). This is further supported by 1,25-D inhibiting autoimmune 
encephalomyelitis, an animal model for MS (36,15). 
 
 
E. Vitamin D and adiposity 
 
To understand the role of vitamin D in obesity it is important understand 
correlations at the population levels. Epidemiologic studies conducted on 
different populations have examined the role of vitamin D and adiposity. Both 
metabolites of interest 1,25-D and 25-D have been studied in relation to obesity. 
25-D which is the circulating form of vitamin D is negatively correlated with body 
fat content and BMI (20,32). 1,25-D has shown inconsistent results in some 
studies suggesting higher levels in obese individuals (20). However, a more 
recent study has noted lower 1,25-D levels in obese as compared to normal 
weight individuals (20). It was also noted that these individuals had higher iPTH 
levels which can be attributed due to low 1,25-D levels (20). The study suggested 
that a low serum 25-D level was due to decreased availability of vitamin D and 
their increased sequestration in fat. Although the iPTH levels were high there still 
was lower levels of 1,25-D. The study suggests that the decreased 25-D levels 
as a possible reason (20). However, 1,25-D has a very short half life in the blood 
and is not a reasonable marker of an individual’s vitamin D status.  Obese 
African-Americans showed higher prevalence of hypovitaminosis D indicating 
race as another factor in this correlation (32).  A study of preoperative morbidly 
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obese patients scheduled for bariatric surgery found 62% of them to have 25-D 
levels below normal and those with normal levels were in the lower quartile (49). 
There is substantial evidence which supports that obese individuals have a 
compromised vitamin D status in comparison to lean individuals.   
 
 
F. Vitamin D and adipocyte differentiation 
 
Preosteoblasts and preadipocyte arise from common progenitor 
mesenchymal stem cells in the bone marrow (29, 12). Vitamin D influences bone 
osteoblast differentiation (29,12). It is hence possible that 1,25-D could share 
common mechanisms and play an important role in adipocyte differentiation too 
(29). 
The inhibitory role of 1,25-D on adipocyte differentiation was first 
demonstrated 20 years ago in 2 different studies (24,10). These studies were 
conducted using 3T3-L1 preadipocytes and 1,25-D treated cells showed a 50% 
decrease in the triglyceride accumulation as compared to the control (24,10). 
Similar results were also seen in ST-13 preadipocyte cell line (24).  These 
studies predicted a receptor-mediated action of 1,25-D on preadipocyte 
differentiation inhibition (24). However, studies done on rat calvaria cells and rat 
bone marrow cells suggested an opposite role for 1,25-D in the  differentiation 
process suggesting that it promoted differentiation in  these cells (1). Similar 
studies conducted on primary human adipocytes demonstrated that 1,25-D 
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stimulates fatty acid synthase (FAS) and suppresses UCP-2 and leptin 
production (26, 13).  Another study by Vu et al (12) showed an increase in LPL 
expression in the cells and media followed by an increase in the expression of 
the adipogenic gene aP2 in 1,25-D treated 3T3-L1 cells.  Despite conflicting 
results in other cell models, research involving 3T3-L1 preadipocytes 
demonstrated mostly consistent results for1,25-D as an inhibitor of adipocyte 
differentiation (7, 3, 13, 10, 24).   
Research by Hida et al (7) highlighted some of the molecular mechanism that 
were involved in 1,25-D linked inhibition.The study showed that 1,25-D inhibited 
adipocyte differentiation by inhibiting PPARγ2 expression suggesting that 1,25-D 
inhibits adipocyte differentiation in the early stages (7). However, 1,25-D 
concentration used in this study was 1µM  which is very high (7). The 
identification of the vitamin D response element in the promoter region of Insig-2 
(insulin induced gene-2) highlights another novel mechanism for the inhibitory 
effects of 1,25-D. Insig-1 and Insig-2 are proteins present in the endoplasmic 
reticulum which can block sterol regulatory element-binding proteins (SREBPs) 
(14).  SREBPs are required for transcriptional activation of synthesis of 
cholesterol and fatty acid. They can also block adipogenesis and lipogenesis (14). 
The study by Lee et al identified the presence of VDRE in the promoter region of 
Insig-2 which binds to the VDR and RXR heterodimer and activates the 1,25-D 
mediated effects (14). They hypothesized that in addition to blocking transcription 
of PPARγ, 1,25-D further blocks adipogenesis by upregulation of Insig-2 (14). 
1,25-D mediated upregulation of Insig-2 could also potentially have effects on 
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lipogenesis in mature adipocytes as SREBPs are required for lipogenesis (14). 
Two recent studies have conducted a detailed analysis on the molecular 
mechanisms involved in the 1,25-D induced inhibition in 3T3-L1 cells (13,3). The 
following are some of the important observations demonstrated by these studies. 
1,25-D inhibits 3T3-L1 adipocyte differentiation in a dose dependent manner and 
is time sensitive (3,13). This suggests that 1,25-D can affect differentiation if 
introduced early in the differentiation program. VDR is expressed early on in 
adipogenesis and the VDR levels decrease with the progress of differentiation 
(13, 3). Mature adipocytes do not express VDR. It is the liganded VDR that can 
inhibit differentiation. This is the potential reason for the time-sensitive inhibition 
by 1,25-D.  Furthermore, expression of major adipogenic genes associated with 
early and late stages of differentiation like PPARγ, C/EBPα, LPL and aP2 were 
blocked by 1,25-D in a dose dependent manner. Genes like SREBP-1c and fatty 
acid synthase (FAS) which are upregulated in mature adipocytes were also 
suppressed by 1,25-D (13).  VDR expression is critical for 1,25-D inhibition as 
VDR binding to 1,25-D mediates most functions of 1,25-D. Kong et al studied this 
aspect by differentiating VDR+/+ and VDR -/- mouse embryonic fibroblasts. 1,25-
D treatment blocked adipogenesis in VDR+/+ cells but failed to do so in VDR-/- 
cells (13). Kong et al (13) have demonstrated that direct suppression of PPARγ 
and C/EBPα by 1,25-D is the main reason for the inhibition. They have further 
explained that 1,25-D and PPARγ both require RXR binding for their action and 
as VDR binds to RXR early in adipogenesis there is very less RXR for the PPARγ 
activation (13). However, Blumberg et al (3) have demonstrated that 1,25-D 
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suppresses C/EBPβ expression which indirectly downregulates PPARγ and 
C/EBPα expression and hence the inhibition of adipogenesis. They have also 
demonstrated that 1,25-D upregulates ETO/MTG8 which is a corepressor for 
C/EBPβ which could further cause the inhibition (3). However, the role of C/EBPβ 
in upregulation of PPARγ and C/EBPα is not clearly understood and is under 
much debate. Both studies have demonstrated a dose dependent and time 
sensitive 1,25-D induced inhibition of adipocyte differentiation at concentrations 
ranging from 1nmol/l to 100nmol/l (3,13). The studies also demonstrate different 
roles for the unliganded VDR. Blumberg et al suggest that unliganded VDR may 
promote adipogenesis and lipid accumulation in adipocytes (3), whereas Kong et 
al (13) suggest the opposite demonstrating an inhibitory effect of the unliganded 
VDR on adipogenesis. They further confirm their hypothesis by demonstrating 
that overexpression of hVDR completely blocks adipogenesis (13). They also 
suggest that 1,25-D binding to VDR stabilizes its levels which usually decrease 
few hours after induction of differentiation if unliganded and this is another 
possible mechanism for 1,25-D induced inhibition (13). These 2 studies have 
very clearly demonstrated an important regulatory role for 1,25-D in the adipose 
tissue biology. Figure 5, shows the potential molecular mechanism through which 
1,25-D inhibits the differentiation process. +, means positively increase 
expression of the transcription factor. -, means downregulates or inhibits 
expression of the transcription factor. 1,25-D when introduced during induction of 
differentiation either blocks PPARγ activity directly or indirectly by blocking 
C/EBPβ which negatively regulates PPARγ. Another mechanism is 1,25-D binds 
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to VDRE (vitamin D response element) on the insig gene and increases Insig-2 
(insulin-induced gene-2) expression. Insig-2 negatively regulates SREBP-1c and 
thereby blocks adipogenesis.  
These effects seen in vitro have yet to be demonstrated in vivo. The 
expansion of the role of 1,25-D from its classical target organs like bone and 
intestine to other tissues like adipocyte, prostate etc has highlighted novel 
functions for this sunshine vitamin.  It is of interest to examine the role of other 
vitamin D metabolites in these tissues. Serum concentration of 25-D is higher 
than any other vitamin D metabolite and it has the longest half life (3 weeks) (2). 
Furthermore, 1,25-D levels in the serum are in picomolar concentrations, have a 
very short half life and can be toxic at higher concentrations due to its 
hypercalcemic effect. It is therefore of interest to look at the role of 25-D in the 
differentiation process. The presence of the renal 1α-hydroxylase in extra renal 
tissues like prostate, placenta, breast and colon (16) elucidates a possible 
paracrine regulation for 1,25-D. To the best of our knowledge no studies have 
been conducted so far examining the role of 25-D on adipocyte differentiation.  
Thus studying the effect of 25-D on the differentiation process and the 
consequent expression of the enzyme 1α-hydroxylase in the adipocytes will 
highlight a possible local regulation of vitamin D within adipocytes.    
Hence the hypothesis for the current research is: 
(i) 25- D, the circulating form of vitamin D will inhibit the MDI-induced adipocyte 
differentiation of 3T3-L1 preadipocytes. 
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(ii)  We also hypothesize that the inhibitory effects of 25-D will show decreased 
expression of the key adipogenic transcription factor PPARγ and the expression 
of 1α-hydroxylase enzyme in these cells.  
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Figure: 5. Potential molecular mechanism for 1,25-D induced inhibition of 
Adipogenesis. +, means positively increase expression of the transcription factor. 
-, means downregulates or inhibits expression of the transcription factor. 1,25-D 
when introduced during induction of differentiation either blocks PPARγ activity 
directly or indirectly by blocking C/EBPβ which negatively regulates PPARγ. 
Another mechanism is 1,25-D binds to VDRE (vitamin D response element) on 
the insig gene and increases Insig-2 (insulin-induced gene-2) expression. Insig-2 
negatively regulates SREBP-1c and thereby blocks adipogenesis.  
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CHAPTER II 
EXPERIMENTAL DESIGN / METHODS 
 
A. Cell Culture and Differentiation 
 
3T3-L1 cells (ATCC) were cultured in growth media constituting 89% Dulbecco’s 
modified Eagle’s medium (DMEM) obtained from Sigma-Aldrich, 10% calf serum 
(Sigma) and 1% penicillin/streptomycin (Gibco). The media was changed with 
fresh growth media every 48 hours. The cells were allowed to get 100% 
confluent. Two days post confluence differentiation was initiated. The 3T3-L1 
cells was treated with differentiation media consisting of 0.5 mM 3-isobutyl-1-
methylxanthine (MIX, Sigma), 1µM dexamethasone, 1.74 µM insulin (Sigma), 
10% fetal bovine serum (Sigma), 1% penicillin/streptomycin and 87% DMEM. 
1,25-dihydroxyvitamin D (Biomol Inc) was added at concentrations of 1 nmol/L, 
10 nmol/L, 100 nmol/L and 0.1 nmol/L at the time of induction of differentiation.  
25-hydroxyvitamin D was added at concentrations of 100 nmol/L, 250 nmol/L, 
500 nmol/L, 750 nmol/L and 1000 nmol/L. The vehicle consisted of cells treated 
with 0.01% ethanol. The media was changed 48 hours post-induction to a media 
containing DMEM, fetal bovine serum, insulin and penicillin/streptomycin. 
Treatment compounds were added at same concentrations when media was 
changed. The extent of differentiation was assessed using Oil red O staining 
done on Day 6 of differentiation and through visual observations by the 
investigator under the microscope from day 1 through 6. The differentiation 
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experiments were conducted in 6-well plates. All treatment groups were in 
triplicates. 
Cells were collected and harvested to assess mRNA of adipogenic genes 
PPARγ and for 1α-hydroxylase, VDR expression at on Day 6. All result analysis 
was done in triplicates. 
A time course experiment was conducted at the lowest concentration 
showing inhibition for 1,25-D and 25-D treated cells to assess mRNA expression 
of 1α-hydroxylase, VDR for 1,25-D and 25-D at the lowest concentration which 
shows differentiation. The cells were collected and harvested for mRNA 
expression at day 0, 3h, 6h, day 1, day 2 and day 6 during differentiation,  
 
B. Result Analysis 
 
1. Oil Red O Staining 
Oil Red O Stock: Oil Red O stock solution was prepared by mixing Oil red 
O powder (SIGMA Inc) in isopropanol and it is stirred overnight and filtered. This 
was stored at 4C. 
Staining: The cells were collected on day 6 for oil red O staining. The 
media was discarded and 10% formalin was added briefly to the cells. The cells 
were washed with 60% isopropanol and completely dried. The cells were then 
stained with 60:40 Oil red O stock and isopropanol working solution and 
incubated in the Oil red O working solution for 10 min and washed 5 times with 
deionized water. The plates were completely dried and photographs were taken 
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using a digital camera. They were later eluted with 100% isopropyl alcohol and 
measured in a microplate reader at an OD 490nm. The results were expressed 
as mean of values from triplicate samples. 
 
2. RNA Analysis 
RNA Isolation:  
The media was discarded and cells were harvested in TRI reagent 
(Invitrogen Inc) and scraped using a cell scraper. The RNA isolation was done as 
per instructions by the RNA kit supplier. After the phase separation using 
chloroform, the RNA was precipitated using 100% isopropanol and centrifuged. 
The supernatant was discarded and the RNA pellet was washed 3 times using 
75% ethanol and solubilized in DEPC (RNA water). It was then stored at -80C 
until quantification. 
RNA Quantification: 
To measure RNA concentration a small quantity (4µg) of the RNA sample 
was combined in DEPC water and absorption was measured at OD of 260nm on 
a spectrophotometer. 
Agarose Electrophoresis:  
Gel was prepared by mixing 1.5% agarose and Tris acetate-EDTA (TAE) 
buffer. Agarose was dissolved making the solution clear. The loading dye was 
prepared and RNA samples were added and the gel was kept in the 
electrophoresis chamber for 30 minutes. Ethidium bromide (EtBr) was added and 
the plate was read under the illuminator and pictures were taken using a digital 
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camera. Agarose gel electrophoresis was run to check band integrity and quality 
before RT-PCR. The final mRNA expression after PCR running for gene of 
interest was also run on agarose gel electrophoresis. 
RT-PCR: 
Semiquantitative RT-PCR method was used to assess gene expression. 
The cDNAs were synthesized using SuperScript III First-Strand Synthesis 
System for RT-PCR kit (Invitrogen Inc) as per the protocol provided by 
manufacturer.   
PCR of the first strand cDNA was performed using Platinum Blue PCR Supermix 
96 kit (Invitrogen Inc). The cDNA was amplified for gene of interest using the 
respective primer sequence. The gene sequence for PPARγ primer were as 
follows: forward, 5’-CCA GAG TCT GCT GAT CTG CG-3’ and reverse, 5’-GCC 
ACC TCT TTG CTC TGA TC-3’. PCR conditions for PPARγ were annealing 
temperature of 58C with 35 cycles. Sequence for the loading control primer 
GAPDH was forward, 5’- CAA GGT CAT CCA TGA CAA CTT TG-3’ and reverse, 
5’- GGC CAT CCA CAG TCT TCT GG – 3’. The PCR conditions for GAPDH was 
annealing temp at 60C and 40 cycles. The protocol used were as per provided by 
the manufacturer. The intensity of the PCR products were measured on agarose 
gel and pictures were taken using a digital camera. Band intensity was quantified 
using the NIH software ImageJ (Image Processing and Analysis in Java). 
Relative band intensity of PPARγ was calculated against the loading control 
GAPDH for all samples and the fold induction was calculated. 
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C. Statistical Analysis 
The statistical tool used was SAS. The results were represented as mean + SD. 
The ANOVA was used to assess the variability and Duncan t-test was  used to 
assess statistical significance between treatment groups for the oil red o staining 
results. Scheffe’s test was used for post hoc analysis and to control for 
experiment wise error. The statistical significance was assessed at p-value < 
0.05. The treatment groups which exhibited large cell death were excluded from 
the analysis. MS Excel tool was used to calculate relative band intensity 
quantified using NIH software ImageJ for target genes of interest by dividing with 
the loading control GAPDH and fold induction for mRNA expression was 
measured.  
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CHAPTER III 
RESULTS 
 
A. 1,25-dihydroxyvitamin D inhibits differentiation of 3T3-L1 preadipocytes: 
1,25-D was added to the differentiation media on day 0 which is the day of 
the initiation of differentiation. Oil red O staining was used to assess the degree 
of differentiation and was assessed on day 6 of differentiation. High color 
intensity suggests increased differentiation and triglyceride accumulation. 
Consistent with previous studies 1,25-D significantly inhibited differentiation at 
concentrations of 100 nmol/l, 10 nmol/l, 1 nmol/l and 0.1 nmol/l (3, 13). Figure 6 
shows the oil red o staining pictures as observed on day 6. The cells treated with 
1,25-D at 1 nmol/l and 0.1 nmol/l showed decreased color intensity as compared 
to the control suggesting decreased lipid accumulation and inhibition of 
differentiation. The degree of inhibition was highest in cells treated with100 nmol/l.  
We observed high cell death or apoptosis in adipocytes treated with 10 nmol/l 
and greater concentrations of 1,25-D. We did not further evaluate the cause for 
apoptosis as it was not within our research interest so for further experiments we 
used concentrations of 1,25-D where we did not observe cell death.   
 
B. 25-hydroxyvitamin D inhibits differentiation of 3T3-L1 preadipocytes: 
The prohormone 25-D was added on day 0 during initiation of 
differentiation at various concentrations and degree of differentiation was 
measured using Oil red O staining. 25-D also inhibited differentiation of 3T3-L1 
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cells at concentrations equal to or above 500 nmol/l. This inhibition was        
dose-dependent and significant at concentrations greater than or equal to       
500 nmol/l. There was a small increase seen at 100 nmol/l and some inhibition 
seen at 250 nmol/l, although both were not significant.  High cell death or 
apoptosis was observed in cells treated with 750 nmol/l and 1000 nmol/l of 25-D 
suggesting possible toxic concentrations. Similar to 1,25-D we used only those 
concentrations of 25-D which showed no cell death.  Figure 7, shows the Oil red 
O staining pictures of cells treated with different concentrations of 25-D. The 
color intensity is lower in 25-D treatment groups as compared to the control 
(0.01% ethanol+MDI) which has highest red color intensity on day 6 suggesting 
high percent of differentiation. Inhibition is seen at 500 nmol/l, 750  nmol/l and 
1000nmol/l 25-D treatment concentration. Figure 9 shows the summary of 
percent differentiation seen at various concentrations of 1,25-D and 25-D 
treatment as compared to the control (0.01% ethanol +MDI). The concentrations 
shown here are those where no cell death or toxicity was seen. The inhibition 
was statistically significant at 500 nmol/l for 25-D group and 1 nmol/l and 0.1 
nmol/l for1,25-D concentrations. The values represent results from 4 independent 
experiments.  There was no inhibition seen at 100 nmol/l   25-D. 
 We further evaluated the mRNA expression of PPARγ which is a key 
adipogenic gene at various concentrations of 25-D and 1,25-D. Studies have 
shown that it is the driving force for the differentiation process and decrease in its 
expression is consistent with inhibition of the adipogenic program (48). Figure 10, 
shows PPARγ and GAPDH mRNA expression at various concentrations of 25-D 
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and 1,25-D and the relative band intensity of PPARγ to GAPDH.  It suggests a 
decrease in expression seen in cells treated with 1nmol/l showing a fold of 0.18 
and a fold of 0.26 for 0.1nmol/l of 1,25-D after normalization for loading control 
GAPDH. PPARγ expression also is decreased at 25-D concentrations of 
500nmol/l with a fold of 0.66 which is lower than the Day 0 control.  
 
C. Time course evaluation of adipogenic gene PPARγ and vitamin D related 
genes: 
 Based on the results from the first phase of experiments we chose the 
least concentration at which significant inhibition of differentiation was seen in 
1,25-D and 25-D to do a time course evaluation of expression of various vitamin 
D related  genes during the differentiation process . We chose 500nmol/l for 25-D 
and 1nmol/l for 1,25-D. The time points used were 0h (day 0), 3h, 6h, 24h (day 1), 
48h (day 2) and 144h (day 6). Inhibition of differentiation was seen as expected 
in 1,25-D and 25-D treatments on day 6. Figure 8 shows the Oil red O staining on 
day 6 for the treatment groups. Both 1nmol/l 1,25-D and 500nmol/l 25-D show a 
decreased red color intensity as compared to the control suggesting inhibition of 
differentiation. We further evaluated gene expression of the key adipogenic 
transcription factor PPARγ mRNA gene expression during the course of 
differentiation. The PPARγ gene expression in the control group shows a gradual 
increase in the mRNA expression during the course of differentiation. This is 
consistent with literature findings (3, 13). There was a decrease in gene 
expression of PPARγ mRNA on Day 6 seen in 1,25-D (0.1 nmol/l) and 25-D (500 
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nmol/l) treated cells. Figure 11 is the gene expression and fold change for PPARγ 
after normalization for the loading control GAPDH as seen on day 6. It shows a 
decrease in the amplicon of the bands of PPARγ in the 1,25-D (1 nmol/l) and 25-
D (500 nmol/l) on day 6. The fold change for 1,25-D was lower than the day 6 
control findings showing a 2 fold decrease as compared to the control and a 
similar decrease was seen in the 25-D group mRNA expression . This inhibitory 
effect of both 1,25-D and 25-D correlates with decreased PPARγ gene 
expression. However, as the sample size was n=1 more repeats need to be done 
to confirm these findings. Also consistent with previous studies PPARγ 
expression increases gradually during the process of differentiation (3, 13). 
Figure 11, also shows the increase in the PPARγ mRNA expression at 0, 3, 6, 
12h, day 1, day 2 and day 6 in the control 1,25-D treated cells and in 25-D 
treated cells.  
We evaluated the gene expression of vitamin D related genes including 
1α-hydroxylase, VDR and 24-hydroxylase using real time RT-PCR conducted at 
Tufts University. The results suggest the presence of 1α-hydroxylase in 3T3-L1 
cells. The expression of which occurs early during the differentiation process. 
Figure 12 shows the results from the real time RT-PCR for presence of 1α-
hydroxylase at different time points in the control, 1,25-D and 25-D treated cells. 
The expression of which seems to peak at 6h and decreases as the 
differentiation process progresses suggesting that it is expressed early in the 
differentiation.  1α-hydroxylase expression appears to decline with initiation of 
differentiation. The 1α-hydroxylase expression in all 3 groups peaks at 6h point, 
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however the vitamin D metabolites show a smaller peak in the 1α-hydroxylase 
expression as compared to the control group. The VDR mRNA is also expressed 
early in the adipogenic process and decreases as the differentiation progresses. 
Figure13 shows that VDR expression in all 3 treatment group and it peaks at 6h 
in the control group. However the same peak is not seen in the 1,25-D and 25-D 
treated cells. This could be suggestive that the vitamin D metabolites appear to 
inhibit VDR mRNA expression. However VDR is expressed early in the 
adipogenic process in all 3 groups. The VDR results are consistent with previous 
studies conducted in this cell model (3, 13). These results are from experiments 
with a small sample size n=1. The enzyme 24-hydroxylase can be induced with 
the addition of both vitamin D metabolites. Figure 14, shows the 24-hydroxylase 
activity at various time points during differentiation with addition of vitamin D 
metabolites. It appears that 1,25-D as well as 25-D can induce 24-hydroxylase 
activity, however 1,25-D shows higher upregulation as compared to 25-D. This 
gene expression is highest at the 24h point in the 1,25-D treated cells. The 24-
hydroxylase expression in 25-D treated cells was highest at the 6h point and 
decreases on day 1 (24h). The control did not show any 24-hydroxylase 
expression. This result needs to be repeated as the control data was missing for 
day 6. However it is important to note that the real time RT-PCR results of the 
vitamin D related genes are preliminary and have been conducted using a small 
sample size (n=1). These results need to be repeated on a larger sample. 
However there are some suggestive trends and consistencies in the key vitamin 
D related genes. 
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Figure: 6. Oil red O pictures of 1,25-D treated 3T3-L1 cells. 1,25-
dihydroxyvitamin D treated 3T3-L1 cells assessed on day 6 inhibit the 
differentiation into mature adipocyte. Higher color intensity suggests increased 
differentiation. 3T3-L1 cells were cultured in GM- growth media; Con - control 
0.01% ethanol+MDI and various concentrations of 1,25-D. 
 
  
Figure: 7. Oil red O pictures of 25-D treated 3T3-L1 cells.  25-hydroxyvitamin D 
treated 3T3-L1 cells assessed on day 6 inhibit differentiation. Higher color 
intensity suggests increased differentiation or lipid accumulation. 3T3-L1 cells 
were cultured in GM- growth media; Con- control 0.01% ethanol+MDI and 
various concentrations of 25-D. 
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Figure: 8. Oil red O pictures of 3T3-L1 cells treated with vitamin D metabolites in 
Phase II.  Results as seen on Day 6 of differentiation. 
 
Figure: 9. The summary of results of Oil red O staining assessed on Day 6. The 
graph shows the percentage of differentiation seen in each treatment group 
against the control. The post hoc analysis by Scheffe’s test for pairwise 
comparison was significant between the control and 25-D 500 nmol/l; 1,25-D 0.1 
nmol/l and 1,25-D 1 nmol/l (p<0.05). The results are values from 4 independent 
experiments (n=4). 
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Figure: 10. PPARγ mRNA expression on Day 6 of differentiation at various 
concentrations of 1,25-D and 25-D. 3T3-L1 cells were harvested on day 6 and 
mRNA were isolated for various concentrations of 1,25-D and 25-D. 
Semiquantitative RT-PCR was performed for PPARγ and GAPDH and data was 
quantified after normalization for GAPDH (PPARγ/GAPDH). The results are 
representative of a sample size n=1. 
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Figure: 11. PPARγ mRNA expression at various time points during the 
differentiation in all groups. 3T3-L1 cells were harvested on day 6 and mRNA 
were isolated for various concentrations of 1,25-D and 25-D. Semiquantitative 
RT-PCR was performed for PPARγ and GAPDH and data was quantified after 
normalization with the GAPDH mRNA (PPARγ/GAPDH).  The results are 
representative of a sample size n=1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 0 3  h o u r 6  h o u r 1 2  h o u r D a y  1 D a y  2 D a y  6   
A    B     C      A     B    C     A     B     C      A    B    C      A     B     C      A     B     C
P P A R g
G A P D H
D 0  – D a y  0
A ;  C o n tr o l  (0 .0 1 %  E tO H )
B : 1 ,2 5 D  (1 n m o l/ l )
C :  2 5  D  (5 0 0 n m o l / l )
 PPARr mRNA gene expression pattern.
0.00
5.00
10.00
15.00
20.00
25.00
30.00
0 h 3 h 6 h 12 h 24 h 48 h 144 h
Time points
Fo
ld
 
control
1,25D (1nM)
25D (500nM)
48 
  
Figure: 12. Real Time RT-PCR time dependent expression of 1α-hydroxylase. 
Real Time RT-PCR results of 1α-hydroxylase mRNA gene expression during 
differentiation in all treatment groups. The data was normalized to the GAPDH 
mRNA for all samples. The graph shows the 1α-hydroxylase gene is expressed 
in the control, 1,25-D and 25-D treated 3T3-L1 preadipocytes at different time 
points during differentiation with a peak seen during the first few hours after 
differentiation. The data is representative of a sample size n=1. 
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Figure: 13. Real Time RT-PCR time dependent expression of VDR. Real time 
RT-PCR was performed for VDR mRNA and the data was quantified after 
normalization for GAPDH expression. The graph shows that VDR gene is 
expressed in all the three treatment groups early during the differentiation 
process peaking at the 6hour time point in the control. The vitamin D metabolites 
appear to have decreased expression of this gene. The data is representative of 
a sample size n=1. 
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Figure: 14. Real Time RT-PCR time dependent expression of 24-hydroxylase. 
Real time RT-PCR was performed for 24-hydroxylase mRNA at various time 
points during differentiation and the data was quantified after normalization for 
GAPDH expression. The graph suggests that both vitamin D metabolites can 
induce     24-hydroxylase gene expression in 3T3-L1 cells.  The gene expression 
peaks early during the course of differentiation and is highly induced by 1,25-D. 
The data is representative of a sample size n=1. 
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CHAPTER IV 
DISCUSSION 
 
 The 3T3-L1 cell line is a good model to study the adipogenic program. 
Several studies have shown that 1,25-D inhibits adipogenesis (3, 10, 13, 24) and 
our study also demonstrated the inhibitory role of 1,25-D. However to the best of 
our knowledge no study has looked at the role of the prohormone 25-
hydroxyvitamin D in adipogenesis and the current study attempts to understand 
its role and the gene expression of the key enzymes of vitamin D metabolism 
involved in this process. To investigate this role, we conducted a series of 
differentiation experiments with 25-D treatment using the 3T3-L1 cell model and 
evaluated the expression of important adipogenic and vitamin D related genes. 
25-D is the prohormone metabolite of vitamin D. It is the most abundant form of 
vitamin D in the circulation. This prohormone can be converted to 1,25-D by the 
renal enzyme 1α-hydroxylase. 1,25-D is the active form of vitamin D and is 
responsible for the vitamin D related effects. Recent studies have identified the 
presence of the enzyme 1α-hydroxylase in extrarenal tissues such as breast, 
prostate, lung, placenta etc suggesting a possible paracrine regulation of vitamin 
D different from its traditional endocrine role (16, 54, 55, 56). This interesting find 
in other tissues was the basis for investigating the role of 25-D in the 3T3-L1 
preadipocytes and if there is the presence of 1α-hydroxylase in these cells.  
  Our results demonstrate that 25-D can significantly inhibit differentiation of 
3T3-L1 preadipocytes at concentrations equal to and greater than 500 nmol/l. 
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There is a clear difference in the color intensity by Oil red O staining between the 
control group and the 25-D treated cells. To demonstrate the validity of the 
methods used in our experiments we conducted the differentiation experiments 
with the addition of 1,25-D to the cells and we found an inhibitory effect similar to 
findings from previous studies (3, 10, 13). One in vitro study conducted by Rook 
et al (56) studied the effect of various vitamin D metabolites including 25-
hydroxyvitamin D to control proliferation of M.tuberculosis in human monocytes. 
All metabolites inhibited the proliferation of M.tuberculosis and 25-hydroxyvitamin 
D caused inhibition at higher concentrations as compared to 1,25-D (56). Our 
results were similar in that 25-D caused inhibition of differentiation at higher 
concentrations as compared to 1,25-D.  To further validate our Oil red O findings 
we studied the gene expression of PPARγ a key adipogenic transcription factor. It 
is an important factor promoting the development of the mature adipocyte from 
preadipocytes (19, 23). Studies suggest that several factors like C/EBPβ , 
SREBP-1c may activate PPARγ but no other transcription factor can promote 
adipogenesis in the absence of PPARγ (10, 19, 23). Similar to previous studies 
our results also demonstrated a decrease in PPARγ mRNA expression in the 
1,25-D treated cells(3, 13) and a similar decrease in expression of PPARγ was 
seen in the 25-D treated cells. This is suggestive that the mechanism for the 
inhibitory effect seen in 25-D treated cells is also through the decreased 
expression of the key adipogenic transcription factor PPARγ.  
 We further evaluated gene expression of important vitamin D related 
genes like 1α-hydroxylase, VDR and 24-hydroxylase using real time RT-PCR 
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and observed promising trends. VDR and 1α-hydroxylase were expressed in the 
3T3-L1 cells at various time points during the course of differentiation and 24-
hydroxylase was induced by both vitamin D metabolites. In general, VDR gene 
was expressed early on during differentiation and decreased during the course of 
differentiation in all the groups. The VDR gene peaked between 3 and 6h after 
initiation of differentiation and decreased there on, consistent with results seen in 
studies by Blumberg et al and Kong et al studies (3, 13). However, we observed 
that the peak in VDR mRNA was highest in the control and both 1,25-D and 25-D 
treated cells showed smaller peaks. This suggests that the vitamin D metabolites 
may inhibit VDR expression. Previous studies have found that both PPARγ and 
VDR need to bind to retinoic acid receptor (RXR) for their action and they may 
compete with each other for RXR (3, 13). VDR binding to 1,25-D is required for 
1,25-D to exert its effects (3,13). It is possible that RXR binds with the VDR early 
in the differentiation process makes it less available for PPARγ binding and 
hence causes the decrease in its expression in the 1,25-D and 25-D treated cells 
(13). Further, this decrease in PPARγ expression may cause the inhibition of 
differentiation seen with the addition of vitamin D metabolites. The early 
expression of VDR mRNA has been demonstrated by other studies and is 
suggested to be driven by the cAMP pathway. The same pathway is known to 
activate VDR in other cell types (3). Blumberg and colleagues (3) demonstrated 
that 3-isobutyl-1-methylxanthine which is a component of the MDI hormonal 
cocktail used to induce differentiation strongly induced VDR 6h after its addition. 
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This is consistent with the cAMP pathway driven induction of VDR and is the 
responsible for its early expression of the VDR mRNA (3).  
 In the present study 1α-hydroxylase mRNA was expressed in the 3T3-L1 
cells. Similar to the VDR mRNA, 1α-hydroxylase expression appears to peak 
early during the differentiation process at the 6 hour point. The addition of the 
vitamin D metabolites after initiation of differentiation is associated with a 
decrease in the 1α-hydroxylase gene expression. However a peak in expression 
was noted at the same time point of 6 h in the cells treated with 1,25-D and 25-D 
similar to the control group.  It is known that 1,25-D is a negative regulator of 1α-
hydroxylase and upregulates 24-hydroxylase activity at an endocrine level in the 
body which could potentially explain a similar negative effect in its expression on 
addition of 1,25-D at the tissue specific level (27). It has also been suggested 
that the liganded VDR can repress the 1α-hydroxylase promoter. The liganded 
VDR binds to and blocks the activation function of VDIR (vitamin D interaction 
repressor), which binds and activates the 1α-hydroxylase promoter (3). 1,25-D 
needs to bind to VDR to exert its effects and that could be the mechanism by 
which the vitamin D metabolites are associated with decreased 1α-hydroxylase 
mRNA expression (3). Several studies conducted on cancer cell lines and 
monocytes have demonstrated that 1,25-D can upregulate 24-hydroxylase 
mRNA expression (54, 55, 57). The expression of 1α-hydroxylase, VDR, 24-
hydroxylase in 3T3-L1 cells and the change in their levels seen on addition of 
1,25-D or 25-D could be indicative of a tissue-specific role of vitamin D.  Although 
the trends and consistencies seen in the key vitamin D related genes are very 
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promising, these experiments were conducted on a small sample size and hence 
caution must be exercised in interpreting these results and these observations 
need to be repeated on a larger sample size to confirm our findings. 
 Several in vitro cancer studies have showcased the antiproliferative and a 
tissue specific production of vitamin D (34, 54, 55). There have been studies 
conducted on breast tissues of normal and breast cancer patients that have 
demonstrated the expression of the key vitamin D enzymes with a higher 
expression in breast cancer tissues. These studies have highlighted a 
paracrine/autocrine role of vitamin D (54, 55). Another study which was 
conducted on monocytes showed inhibition of proliferation of M.tuberculosis 
caused by addition of 25-D. This study suggested the presence of 1α-
hydroxylase in these cells which were capable of converting 25-D to its active 
form 1,25-D (56). The study demonstrated that radioactive 25-D got converted to 
a metabolite which cochromatographed with 1,25-D. They also demonstrated 
that more 25-D to 1,25-D conversion occurred with the addition of the lymphokine 
interferonγ (56). A similar role can be predicted for vitamin D in the adipose 
tissue; however more studies need to be conducted confirming our results on 
3T3-L1 preadipocytes and on primary human preadipocytes. To the best of our 
knowledge our study is the first to demonstrate a role for 25-D in the adipocyte 
differentiation process in 3T3-L1 cells and the first to suggest the presence of 1α-
hydroxylase in these cells.  
 In summary, our study has demonstrated that similar to 1,25-D the 
prohormone 25-D also inhibits the adipogenic process in 3T3-L1 cells. This 
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inhibitory effect correlates with the decrease in the expression of PPARγ which is 
a key adipogenic transcription factor. Preliminary findings suggest the presence 
of key vitamin D enzyme 1α-hydroxylase and other genes like VDR.                 
24-hydroxylase can be induced with addition of vitamin D metabolites. Both VDR 
and 1α-hydroxylase are expressed early in differentiation and inhibited with the 
addition of both 1,25-D and 25-D.  
 These results suggest that 25-D is biologically active in 3T3-L1 cells and 
its effects is suggestive of an intracellular conversion of 25-D to its active form 
1,25-D in differentiating cells and a tissue specific effect of vitamin D in 
adipocytes. Further studies involving 25-D in the adipogenic process 
investigating the vitamin D related gene expression in this cell model as well as 
human preadipocytes will help elucidate a possible role for this prohormone 25-D 
in fat cell biology.  With the rise in obesity and its associated comorbidities, the 
role of nutrients like vitamin D could hold clues to understanding the biology of fat 
cells and a possible role in obesity prevention. 
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